Patents by Inventor Naoko Massaki

Naoko Massaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for screening of substance which alter GPR120-mediated cell-stimulating activities
    Patent number: 8399204
    Abstract: The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: March 19, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Tomoko Sekiya, Norimasa Miyamoto, Hirokazu Tanaka, Naoko Massaki
  • Method of screening substance useful in treating disease with the use of GPR40 and phospholipase
    Patent number: 8252521
    Abstract: The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: August 28, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Tomoko Sekiya, Norimasa Miyamoto, Hirokazu Tanaka, Kenichi Morita, Naoko Massaki
  • METHOD FOR SCREENING OF SUBSTANCE EFFECTIVE ON DISEASE USING GPR120 AND PHOSPHOLIPASE
    Publication number: 20110183318
    Abstract: The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.
    Type: Application
    Filed: September 1, 2006
    Publication date: July 28, 2011
    Applicant: EISAI R&D MANAGEMENT CO., LTD
    Inventors: Tomoko Sekiya, Norimasa Miyamoto, Hirokazu Tanaka, Naoko Massaki
  • Method of Screening Substance Useful in Treating Disease With the Use of GPR40 and Phospholipase
    Publication number: 20100227350
    Abstract: The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.
    Type: Application
    Filed: October 17, 2006
    Publication date: September 9, 2010
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Tomoko Sekiya, Norimasa Miyamoto, Hirokazu Tanaka, Kenichi Morita, Naoko Massaki